IBOImpact Biomedical Inc.
Earnings
When Impact Biomedical Inc. reports, what it reported each quarter, and how the stock took the results.
18 quarters. Jun 30, 2022 to Sep 30, 2026. USD.
Next results · Q4 2026Projected
10-K due Feb 16 – Apr 2
No earnings release is on file for this company, so the day is the 10-K’s, projected from its last 3 filings.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Feb 16 – Apr 2
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- —
- Revenue, change from a year earlier: Q3 2026 +16.7%, Q2 2026 −57.1%, Q1 2026 n/m, Q3 2025 n/m
- Net income
- $5.25M
- Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
- EPS
- —
- EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
Latest results
- Revenue
- $21.00K
- +16.7%
- Net income
- -$645.00K
- N/M
- EPS
- -$0.08
- N/M
- Revenue
- $3.00K
- −57.1%
- Net income
- -$699.00K
- N/M
- EPS
- -$0.01
- N/M
- Revenue
- $7.00K
- —
- Net income
- -$2.29M
- N/M
- EPS
- -$0.02
- N/M
- Revenue
- —
- —
- Net income
- $5.25M
- N/M
- EPS
- —
- —
All quarters
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Move | Source trail |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | ||||||||||
| Q3 2026 | Sep 30, 2026 | — | Nov 9, 2026 | 40 d | 10-Q | $21.00K | +16.7% | -$0.08 | +7.7% | |
| Q2 2026 | Jun 30, 2026 | — | Aug 7, 2026 | 38 d | 10-Q | $3.00K | −57.1% | -$0.01 | 4.4% | |
| Q1 2026 | Mar 31, 2026 | — | May 12, 2026 | 42 d | 10-Q | $7.00K | — | -$0.02 | 7.9% | |
| FY 2025 | ||||||||||
| Q4 2025derived | Dec 31, 2025 | — | Mar 11, 2026 | 70 d | 10-K | — | — | — | 1.8% | |
| Q3 2025 | Sep 30, 2025 | — | Nov 7, 2025 | 38 d | 10-Q | $18.00K | — | -$1.52 | +1.8% | |
| Q2 2025 | Jun 30, 2025 | — | Aug 14, 2025 | 45 d | 10-Q | $7.00K | — | -$1.18 | +4.7% | |
| Q1 2025 | Mar 31, 2025 | — | May 14, 2025 | 44 d | 10-Q | — | — | -$0.11 | +2.0% | |
| FY 2024 | ||||||||||
| Q4 2024derived | Dec 31, 2024 | — | Mar 28, 2025 | 87 d | 10-K | — | — | — | 42.8% | |
| Q3 2024 | Sep 30, 2024 | — | Nov 12, 2024 | 43 d | 10-Q | — | — | $0.06 | 1.1% | |
| Q2 2024 | Jun 30, 2024 | — | Aug 13, 2024 | 44 d | 10-Q | — | — | -$0.09 | — | |
| Q1 2024 | Mar 31, 2024 | — | May 10, 2024 | 40 d | 10-Q | — | — | -$0.10 | — | |
| FY 2023 | ||||||||||
| Q4 2023derived | Dec 31, 2023 | — | Feb 20, 2024 | 51 d | 10-K | — | — | — | — | |
| Q3 2023 | Sep 30, 2023 | — | Nov 13, 2023 | 44 d | 10-Q | — | — | -$0.02 | — | |
| Q2 2023 | Jun 30, 2023 | — | Oct 5, 2023 | 97 d | 10-Q | — | — | -$0.02 | — | |
| Q1 2023 | Mar 31, 2023 | — | — | — | — | — | — | -$0.01 | — | |
| FY 2022 | ||||||||||
| Q4 2022derived | Dec 31, 2022 | — | — | — | — | $0.00 | — | — | — | |
| Q3 2022 | Sep 30, 2022 | — | — | — | — | — | — | -$0.03 | — | |
| Q2 2022 | Jun 30, 2022 | — | — | — | — | $50.00K | — | $0.00 | — | |
Earlier years, FY 2022 to FY 2023The latest three years
Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Source filings
Provenance
ProvenanceData status and checks
Impact Biomedical Inc. · CIK 1834105 · Engraved from SEC EDGAR